E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Refractory Eosinophilic Asthma. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate whether mepolizumab effectively suppresses the presence of eosinophils in sputum and whether this translates into a fall in the frequency of asthma exacerbations in a cohort of refractory asthmatics who otherwise require a high dose of inhaled corticosteroids and, in some cases, regular oral corticosteroids to control their asthma. |
|
E.2.2 | Secondary objectives of the trial |
To assess the effects of mepolizumab on: 1. Long term changes in airway structure and function (airway remodelling) after 12 months treatment using bronchial biopsy material and CT scans. 2. Asthma symptoms and quality of life, analysed using diary cards and validated questionnaires. 3. Exhaled nitric oxide levels. 4. Concentration of methacholine required to cause a fall in FEV1 by 20% from baseline. 5. Hospital admission rates over the 12 months. 6. Obtain blood samples for pharmacogenomic analysis by GSK (N.B. This does not form part of the data collection/analysis of this study). |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Refractory asthma as defined by the American Thoracic Society guidelines. 2. Symptoms and objective evidence of variable airflow obstruction as indicated by one or more of the following: i) >15% increase in FEV1 following 200 micrograms inhaled salbutamol. ii) >20% within day variability in PEF noted on any day following assessment twice daily over 2 weeks. iii) and/or a concentration of metacholine causing 20% fall in FEV1 of <8 mg/ml documented at any time during previous assessments at Glenfield Hospital. 3. A history of 2 or more asthma exacerbations in the previous 12 months requiring oral corticosteroids on at least 3 consecutive days, emergency care visit and treatment or hospitalisation. 4. Evidence of eosinophilic airway inflammation - a sputum eosinophil count of greater than 3% in last 2 years. 5. Ability to give written informed consent prior to participation in the study. 6. Availability to complete the study and all measurements. 7. Ability to read, comprehend and write English at a level sufficient to complete study related materials. |
|
E.4 | Principal exclusion criteria |
1. Current smokers or ex smokers with a smoking history of greater than 15 years. 2. Evidence of previous exposure to parasite disease, based on positive parasite serology. 3. History of allergy to antibody therapy. 4. History of an exacerbation or an escalation of treatment in the 2 weeks prior to baseline assessments. Participants can be recruited once they have been stable for at least 2 weeks. 5. History of alcohol or drug abuse. 6. Significant co morbidity pertaining to ischaemic heart disease, severe psychiatric disease and more than two bacterial respiratory tract infections in the last year. 7. Pregnant and lactating females or those women of child bearing potential who do not wish to practice recommended effective contraceptive measures for the duration of the trial period and 100 days after completing the trial. All women of child bearing potential will be required to have a negative pregnancy test prior to study entry. 8. Unexplained abnormal blood tests at screening that are considered a contra indication to proceeding with the trial by the principal investiagtor. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Severe exacerbation frequency over the 12 month treatment period defined as a decrease in the morning peak expiratory flow to more than 30% below the baseline value on 2 or more consecutive days, or a deterioration in symptoms requiring treatment with rescue oral corticosteroids. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial is at the end of the last visit for the last participant, as specified in the study protocol. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |